PBE icon

Invesco Biotechnology & Genome ETF
PBE

Overview Fund Activity

95 hedge funds and large institutions have $105M invested in Invesco Biotechnology & Genome ETF in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 24 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
95
Holders Change
-2
Holders Change %
-2.06%
% of All Funds
1.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
28
Reduced
24
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Morgan Stanley
1
Morgan Stanley
New York
$26M
2
Royal Bank of Canada
2
Royal Bank of Canada
Ontario, Canada
$6.16M
3
LPL Financial
3
LPL Financial
California
$5.47M
4
GKWIM
4
Gerber Kawasaki Wealth & Investment Management
California
$19.8M
5
Wells Fargo
5
Wells Fargo
California
$6.45M

Top Sellers

1
UBS Group
1
UBS Group
Switzerland
$5.07M
2
CAN
2
Cetera Advisor Networks
California
$597K
3
Citadel Advisors
3
Citadel Advisors
Florida
$0
4
Osaic Holdings
4
Osaic Holdings
Arizona
$1.02M
5
BRWA
5
B. Riley Wealth Advisors
Florida
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
Legacy Financial Group (Iowa)
101
Legacy Financial Group (Iowa)
Iowa
– -$9.13K -160 Closed
SCA
102
Stonebridge Capital Advisors
Minnesota
– -$5.7K -100 Closed
WWP
103
WR Wealth Planners
Missouri
– -$5.7K -100 Closed
1 2 3 4
5